alexa Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
Nephrology

Nephrology

Journal of Nephrology & Therapeutics

Author(s): Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B,

Abstract Share this page

Abstract BACKGROUND: Irrespective of their clinical relevance, side effects cannot be considered a negligible problem in antihypertensive therapy. The aim of this trial was to evaluate the tolerability profile of lercanidipine with that of two other calcium antagonists (amlodipine and lacidipine) in elderly hypertensives. METHODS: In a multicenter, double-blind, parallel study 828 elderly (aged > or =60 years) hypertensives were randomized to lercanidipine 10 mg/day (n = 420), amlodipine 5 mg/day (n = 200), or lacidipine 2 mg/day (n = 208) (ratio 2:1:1). If blood pressure (BP) control was unsatisfactory (systolic BP/diastolic BP > or =140/90 mm Hg), the dose of the double-blind medication was doubled and, as a further step, enalapril or atenolol (plus diuretic, if needed) was added. Patients were treated for an average of 12 months. RESULTS: Amlodipine patients had significantly (P <.001) higher rates of edema (19\%) and of early study discontinuations due to edema (8.5\%) compared with lercanidipine (9\% and 2.1\%) and lacidipine patients (4\% and 1.4\%). Similarly, edema-related symptoms (lower limb swelling and heaviness) occurred significantly (P <.01) more often with amlodipine (50\% and 45\%, respectively) than with lercanidipine (35\% and 33\%) and lacidipine (34\% and 31\%). Most edema cases occurred in the first 6 months, a between-treatment difference being evident since beginning of treatment. Other drug-related adverse events did not differ between treatments. Blood pressure was equally and effectively reduced in the three groups. CONCLUSIONS: The two lipophilic dihydropyridine calcium antagonists, lercanidipine and lacidipine, have an antihypertensive effect comparable to that of amlodipine, but a better tolerability profile.
This article was published in Am J Hypertens and referenced in Journal of Nephrology & Therapeutics

Relevant Expert PPTs

Relevant Speaker PPTs

  • Hedef Dhafir El-Yassin
    The Immune Response of Prolactin and the Induction of Tumor Necrosis Factor (TNF) in Iraqi Patients Infected with Hepatitis C Virus
    PPT Version | PDF Version
  • Ahmed Mohammed Ashshi
    The correlations of activins and follistatin with viral load, liver damage, Interleukin-6 and tumour necrosis factor-α in treatment naïve patients with chronic hepatitis C genotype 1 and 4: A case-control study
    PPT Version | PDF Version

Recommended Conferences

  • 15th International Conference on Nephrology & Therapeutics
    August 28-30, 2017 Philadelphia, USA
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • 16th European Nephrology Conference
    October 02-04, 2017 Barcelona, Spain
  • World Nephrology Congress
    Osaka, Japan Oct 09-11, 2017
  • 13th World Nephrology Conference
    October 18-19, 2017 Dubai,UAE
  • 16th International Conference on Nephrology
    NOVEMBER 02-03, 2017 Atlanta, USA

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords